Skip to main content
SpringerLink
Log in
Book cover

Principles of Immunopharmacology pp 265–280Cite as

Anti-allergic drugs

  • Chapter

  • 1400 Accesses

Summary

Allergy is defined as a disease following a response by the IMMUNE SYSTEM to an otherwise innocuous agent. This chapter describes the actions of antiallergic drugs and therapeutics on diseases such as allergic rhinitis, atopic dermatitis, allergic conjunctivitis, systemic anaphylaxis, food ALLERGY, allergic asthma and acute urticaria. The putative MECHANISMS OF ACTION of disodium cromoglycate and nedocromil sodium (chromones) are discussed in detail as well as the biochemical and pharmacological effects, clinical applications and unwanted effects of these drugs. The characterisation of histamine receptors is detailed and the MECHANISMS OF ACTION as well as the observed biological effects of H1 and the relatively new H4 receptors are explained. Further, the biochemical and pharmacological effects of anti-IgE therapy are described and recent clinical trials with these drugs are briefly reviewed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected readings

  • Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (1997) International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharm Rev 49: 253–278 (see also: http://pharmrev.aspetjournals.org/cgi/reprint/49/3/253, accessed December 2004)

    CAS  PubMed  Google Scholar 

References

  1. Eady RP, Norris AA (1997) Nedocromil sodium and sodium cromoglycate: Pharmacology and putative modes of action. In: AB Kay (ed): Allergy and Allergic Diseases. Blackwell, Oxford, 584–595

    Google Scholar 

  2. Eady RP (1986) The pharmacology of nedocromil sodium. Eur J Resp Dis 147: 112–119

    CAS  Google Scholar 

  3. Janssen LJ, Wattie J, Betti PA (1998) Effects of cromolyn and nedocromil on ion currents in canine tracheal smooth muscle. Eur Resp J 12: 50–56

    Article  CAS  Google Scholar 

  4. Rang HP, Dale MM, Ritter JM (1999) The respiratory system. In: L Hunter (ed): Pharmacology. Churchill Livingston, London, 347

    Google Scholar 

  5. Dixon CM, Fuller RW, Barnes PJ (1987) Effect of nedocromil sodium on sulphur dioxide induced bronchoconstriction. Thorax 42: 462–465

    Article  CAS  PubMed  Google Scholar 

  6. Dixon CMS, Ind PW (1990) Inhaled sodium metabisulphate induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol 30: 371–376

    CAS  PubMed  Google Scholar 

  7. Bigby B, Boushey H (1993) Effects of nedocromil sodium on the bronchomotor response to sulfur dioxide in asthmatic patients. J Allergy Clin Immunol 92: 195–197

    Article  CAS  PubMed  Google Scholar 

  8. Yamawaki I, Tamaoki J, Takeda Y, Nagai A (1997) Inhaled cromoglycate reduces airway neurogenic inflammation via tachykinin antagonism. Res Com Mol Pathol Pharmacol 98: 265–272

    CAS  Google Scholar 

  9. Dixon M, Jackson DM, Richards IM (1980) The action of sodium cromoglycate on ‘C’fibre endings in the dog lung. Br J Pharmacol 70: 11–13

    CAS  PubMed  Google Scholar 

  10. Verleden GM, Belvisi MG, Stretton CD, Barnes PJ (1991) Nedocromil sodium modulates nonadrenergic, noncholinergic bronchoconstrictor nerves in guinea pig airways in vitro. Am Rev Respir Dis 143: 114–118

    CAS  PubMed  Google Scholar 

  11. Foreman JC, Hallett MB, Mongar JL (1977) Site of action of the antiallergic drugs cromoglycate and doxantrazole. Br J Pharmacol 59: 473P–474P

    CAS  PubMed  Google Scholar 

  12. Ennis M, Atkinson S, Pearce FL (1980) Inhibition of histamine release induced by Compound F48/80 and peptide 401 in the presence and absence of calcium: implications for the mode of action of anti-allergic compounds. Agents Actions 10: 222–228

    Article  CAS  PubMed  Google Scholar 

  13. Sagi-Eisenberg R (1987) The role of protein kinase C in histamine secretion: implications for the mode of action of the antiasthmatic drug cromoglycate. Curr Topics Pulm Pharmacol Toxicol 2: 24–42

    CAS  Google Scholar 

  14. Sagi-Eisenberg R, Mazurek N, Pecht I (1984) Calcium fluxes and protein phosphorylation in stimulus-secretion coupling of basophils. Mol Immunol 21: 175–181

    Article  Google Scholar 

  15. Lucas AM, Shuster S (1987) Cromolyn inhibition of protein kinase C activity. Biochem Pharmacol 36: 562–565

    Article  CAS  PubMed  Google Scholar 

  16. Mazurek N, Bashkin P, Loyter A, Pecht I (1983) Restoration of Ca2+ influx and degranulation capacity of variant RBL-2H3 cells upon implantation of isolated cromolyn binding protein. Proc Natl Acad Sci USA 80: 6014–6018

    Article  CAS  ADS  PubMed  Google Scholar 

  17. Mazurek N, Geller-Bernstein C, Pecht I (1980) Affinity of calcium ions to the anti-allergic drug, dicromoglycate. FEBS Lett 111: 194–196

    Article  CAS  PubMed  Google Scholar 

  18. Mazurek N, Schindler H, Schurholz T, Pecht I (1984) The cromolyn binding protein constitutes the Ca2+ channel of basophils opening upon immunological stimulus. Proc Natl Acad Sci USA 81: 6841–6845

    Article  CAS  ADS  PubMed  Google Scholar 

  19. Friis UG, Johansen T, Hayes NA, Foreman JC (1994) IgEreceptor activated chloride uptake in relation to histamine secretion from rat mast cells. Br J Pharmacol 111: 1179–1183

    CAS  PubMed  Google Scholar 

  20. Alton EWFW, Norris AA (1996) Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 98: S102–S106

    Article  CAS  PubMed  Google Scholar 

  21. Anderson SD, Rodwell LT, Daviskas E, Spring JF, du Toit J (1996) The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: A role for the airway epithelium? J Allergy Clin Immunol 98: S124–S134

    Article  CAS  PubMed  Google Scholar 

  22. Paulmilchl M, Norris AA, Rainey DK (1995) Role of chloride channel modulation in the mechanism of action of nedocromil sodium. Int Arch Allergy Appl Immunol 107: 416

    Article  Google Scholar 

  23. Armour CL, Johnson PRA, Black JL (1991) Nedocromil sodium inhibits substance P-induced potentiation of the cholinergic neural responses in the isolated innervated rabit trachea. J Auton Pharmacol 11: 167–172

    Article  CAS  PubMed  Google Scholar 

  24. Javdan P, Figini M, Emanueli C, Geppetti P (1995) Nedocromil sodium reduces allergen-induced plasma extavasation in the guinea-pig nasal mucosa by inhibition of tachykinin release. Allergy 50: 825–829

    Article  CAS  PubMed  Google Scholar 

  25. Pelikan Z, Pelikan-Filipek M, Remeijer L (1988) Effects of disodium cromoglycate and beclomethasone dipropionate on the asthmatic response to allergen challenge II. Late response (LAR). Ann Allergy 60: 217–225

    CAS  PubMed  Google Scholar 

  26. Pelikan Z, Pelikan-Filipek M, Schoemaker MC, Berger MP (1988) Effects of disodium cromoglycate and beclomethasone dipropionate on the asthmatic response to allergen challenge I. Immediate response (IAR). Ann Allergy 60: 211–216

    CAS  PubMed  Google Scholar 

  27. Pelikan Z (2001) Late type of the nasal allergic response review. Scripta Medica (BRNO) 74: 303–344

    CAS  Google Scholar 

  28. Larsson K, Larsson BM, Sandstrom T, Sundblad BM, Palmberg L (2001) Sodium cromoglycate attenuates pulmonary inflammation without influencing bronchial responsiveness in healthy subjects exposed to organic dust. Clin Exp Allergy 31: 1356–1368

    Article  CAS  PubMed  Google Scholar 

  29. Hoshino M, Nakamura Y (1997) The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics. Eur Respir J 10: 858–865

    CAS  PubMed  Google Scholar 

  30. James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B, Petzold U (2003) Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opinions 19: 313–320

    Article  CAS  Google Scholar 

  31. Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G (2002) A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 24: 1561–1575

    Article  CAS  PubMed  Google Scholar 

  32. Tauber J (2002) Nedocromil sodium ophthalmic solution 2% twice daily in patients with allergic conjunctivitis. Adv Ther 19: 73–84

    Article  CAS  PubMed  Google Scholar 

  33. Pelikan Z, Pelikan-Filipek M (1989) Effects of oral cromolyn on the nasal response due to foods. Arch Otolaryngol Head Neck Surg 115: 1238–1243

    CAS  PubMed  Google Scholar 

  34. Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van der Wouden JC (2000) Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax 55: 913–920

    Article  CAS  PubMed  Google Scholar 

  35. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB (2002) Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 303: 300–307

    Article  CAS  PubMed  Google Scholar 

  36. Takeshita K, Sakai K, Bacon KB, Gantner F (2003) Critical role of histamine H4 receptor in LTB4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 9: 9

    Google Scholar 

  37. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305: 1212–1221

    Article  CAS  PubMed  Google Scholar 

  38. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49: 253–278

    CAS  PubMed  Google Scholar 

  39. Schneider E, Rolli-Derkinderen M, Arock M, Dy M (2002) Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 23: 255–263

    Article  CAS  PubMed  Google Scholar 

  40. Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG (2000) Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293: 771–778

    CAS  PubMed  Google Scholar 

  41. Ishizaka K, Ishizaka T (1970) Biological function of gamma E antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 6: 25–42.

    CAS  PubMed  Google Scholar 

  42. Macglashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenziewhite J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of Fc epsilon RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158: 1438–1445

    CAS  PubMed  Google Scholar 

  43. Hamelmann E, Rolinck-Werninghaus C, Wahn U (2002) From IgE to anti-IgE: where do we stand? Allergy 57: 983–994

    Article  CAS  PubMed  Google Scholar 

  44. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N (2003) Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111: 278–284

    Article  CAS  PubMed  Google Scholar 

  45. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184–190

    Article  CAS  PubMed  Google Scholar 

  46. Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18: 254–261

    Article  CAS  PubMed  Google Scholar 

  47. Milgrom H, Fick RB, Jr., Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966–1973

    Article  CAS  PubMed  Google Scholar 

  48. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Jr. et al (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100: 110–121

    Article  CAS  PubMed  Google Scholar 

  49. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, et al (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835–1840

    CAS  PubMed  Google Scholar 

  50. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828–1834

    CAS  PubMed  Google Scholar 

  51. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108: E36

    Article  CAS  PubMed  Google Scholar 

  52. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD et al (2000) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106: 253–259

    Article  CAS  PubMed  Google Scholar 

  53. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, et al (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286: 2956–2967

    Article  CAS  PubMed  Google Scholar 

  54. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB (1996) Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279: 1000–1008

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pathophysiology, Faculty of Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands

    Sue McKay

  2. Laboratory of Allergology and Pulmonary Diseases, University Medical Center Groningen, Groningen University, P.O.Box 30.001, 9700 RB, Groningen, The Netherlands

    Antoon J.M. van Oosterhout

Authors
  1. Sue McKay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoon J.M. van Oosterhout
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Pharmacy, Department of Pharmacology and Pathophysiology, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands

    Frans P. Nijkamp

  2. PLIVA Research Institute Ltd., Prilaz baruna Filipovića 29, HR-10 000, Zagreb, Croatia

    Michael J. Parnham

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag

About this chapter

Cite this chapter

McKay, S., van Oosterhout, A.J. (2005). Anti-allergic drugs. In: Nijkamp, F.P., Parnham, M.J. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7408-X_18

Download citation

Publish with us

Policies and ethics

Search

Navigation